1. Introduction MANY millennia ago, the discovery of human kind that fire would irreversibly transform clay into ceramic pottery led eventually to an agrarian society and an enormous improvement in the quality and length of life. Within the last four decades another revolution has occurred in the use of ceramics to improve the quality of life. This revolution is the innovative use of specially designed ceramics for the repair and reconstruction of diseased or damaged parts of the body. Ceramics used for this purpose are termed bioceramics. Bioceramics can be single crystals (sapphire), polycrystalline (alumina or hydroxyapatite (HA)), glass (Bioglass@*), glass-ceramics (Ceravital@+ or A/W glass-ceramic), or composites (stainless-steel-fiber-reinforced Bioglass@ or polyethylene-hydroxyapatite Ceramics and glasses have been used for a long time in the health-care industry for eye glasses, diagnostic instruments, chemical ware, thermometers, tissue culture flasks, and fiber optics for endoscopy. Insoluble porous glasses have been used as carriers for enzymes, antibodies. and antigens since they have several advantages, notably resistance to microbial attack, pH changes, solvent conditions, temperature, and packing under the high pressure which is required for rapid (PE-HA)). *University of Florida, Gainesville, FL 'Leitz Gmbh, Wetrlar. FRG Table I . Types of Implant-Tissue
Response
If the material is toxic, the surrounding tissue dies.
If the material is nontoxic and biologically inactive (nearly inert), a fibrous tissue of variable thickness forms.
flow.' Ceramics are also widely used in dentistry as restorative materials, gold porcelain crowns, glass-filled ionomer cements, dentures, etc. In these applications they are called dental ceramics as discussed by Preston. ' This review is devoted to the use of bioceramics as implants to repair parts of the body, usually the hard tissues of the musculo-skeletal system, such as bones or teeth, although a brief review of the use of carbon coatings for replacement of heart valves is also included. Dozens of ceramic compositions have been tested;',3 however, few have achieved human clinical application. It is now known that clinical success requires the simultaneous achievement of a stable interface with connective tissue and a match of the mechanical behavior of the implant with the tissue to be replaced.
If the material is nontoxic and bio-II. Twes of Bioceramics-Tissue
-.
logically active (bioactive), an interfacial bond forms. Attachment The mechanism of tissue attachment the surrounding tissue replaces it.
response at the implant interface. ' No material implanted in living tissues is inert; all materials elicit a response from living tissues. The four types of response (Table I ) allow different means of achieving attachment of prostheses to the musculo-skeletal system. Table II summarizes the attachment mechanisms, with examples. A comparison of the relative chemical activity of these different types of bioceramics is given in Fig. 1 . The relative reactivity shown in Fig. I (a) correlates very closely with the rate of Dense, nonporous, nearly inert Al2O3 (single crystal and ceramics attach by bone polycrystalline) growth into surface irregularities by cementing the device into the tissues, or by press fitting into a defect (termed morphological fixation). 2 For porous inert implants A1203 (porous polycrystalline) bone ingrowth occurs, Hydroxyapatite-coated porous which mechanically metals attaches the bone to the material (termed biological fixation).
reactive ceramics, glasses, Bioactive glass-ceramics and glass-ceramics attach Hydroxyapatite directly by chemical bonding with the bone (termed bioactive fixation). 4 Dense, nonporous (or porous), Calcium sulfate (plaster of Paris) resorbable ceramics are Tricalcium phosphate designed to be slowly replaced by bone. 3 Dense, nonporous, surfaceBioactive glasses
Calcium phosphate salts formation of an interfacial bond of implants with bone ( Fig. l(b) ). 4 Figure l(b) will be discussed in more detail in Section VIII. The relative level of reactivity of an implant influences the thickness of the interfacial zone or layer between the material and tissue. Analysis of failure of implant materials during the last 20 years generally shows failure originating from the biomaterial-tissue int e r f a~e .~,~ When a biomaterial is nearly inert (type 1 in Table I 1 and Fig. 1 ) and the interface is not chemically or biologically bonded, there is relative movement and progressive development of a nonadherent fibrous capsule in both soft and hard tissues. Movement at the biomaterial-tissue interface eventually leads to deterioration in function of the implant or the tissue at the interface or both. The thickness of the nonadherent capsule varies greatly depending upon both material ( Fig. 2 ) and extent of relative motion.
The fibrous tissue at the interface with dense, medical-grade alumina implants can be very Consequently, as discussed later, if alumina implants are implanted with a very tight mechanical fit and are loaded primarily in compression, they are successful clinically. In contrast, if a type 1, nearly inert, implant is loaded such that interfacial movement can occur, the fibrous capsule can become several hundred micrometers thick and the implant loosens quickly. Loosening invariably leads to clinical failure, for a variety of reasons, including fracture of the implant or the bone adjacent to the implant. Bone at an interface with a type 1, nearly inert, implant is very often structurally weak because of disease, localized death of bone (especially if so-called bone cement, poly(methy1 methacrylate (PMMA) is used), or stress shielding when the higher elastic modulus of the implant prevents the bone from being loaded properly.
The concept behind nearly inert, microporous bioceramics (type 2 in Table II and Fig. 1 ) is the ingrowth of tissue into pores on the surface or throughout the implant, as originated by Hulbert et aL3 many years ago. The increased interfacial area between the implant and the tissues results in an increased inertial resistance to movement of the device in the tissue. The interface is established by the living tissue in the pores. Figure 3 shows living bone grown into the pores of an alumina bioceramic. This method of attachment is often termed biological fixation. It is capable of withstanding more complex stress states than type 1 implants, which achieve only morphological fixation." The limitation associated with type 2 porous implants, however, is that, for the tissue to remain July 1991 viable and healthy, it is necessary for the pores to be greater than 100 to 150 p m in diameter (Fig. 2) . The large interfacial area required for the porosity is due to the need to provide a blood supply to the ingrown connective tissue. Vascular tissue does not appear in pores which measure less than 100 pm. If micromovement occurs at the interface of a porous implant, tissue is damaged, the blood supply may be cut off, tissues die, inflammation ensues, and the interfacial stability can be destroyed. When the material is a metal, the large increase in surface area can provide a focus for corrosion of the implant and loss of metal ions into the tissues, which may cause a variety of medic a I pro b I em s These pot en t i a I problems can be diminished by using a bioactive ceramic material such as HA as a coating on the porous metal, as first shown by Ducheyne et a/. ' The HA coating also speeds the rate of bone formation in the pores. However, the fraction of large porosity required for bone growth in any material degrades the strength of the material. Consequently, this approach to solving interfacial stability is best when used as porous coatings or when used as unloaded space fillers in tissues.
Resorbable biomaterials (type 4 in Table II and Fig. 1 ) are designed to degrade gradually over a period of time and be replaced by the natural host t i s~u e . '~-'~ This leads to a very thin or nonexistent interfacial thickness (Fig. 2) . This is the optimal solution to the problem of biomaterials if the requirements of strength and short-term performance can be met. Natural tissues can repair themselves and are gradually replaced throughout life by a continual turnover of cell populations. As we grow older, the replacement of cells and tissues is slower and less efficient, which is why parts "wear out," unfortunately some faster than others. Thus, resorbable biomaterials are based on the same principles of repair Table II and Fig. 1 ). The concept of bioactive materials is intermediate between resorbable and b i~i n e r t . ' ,~'~ A bioactive material is one that elicits a specific biological response at the interface of the material which results in the formation of a bond between the tissues and the material (shown first in 1969). '4 This concept has now been expanded to include a large number of bioactive materials with a wide range of rates of bonding and thickness of interfacial bonding layers (Figs. 1 and 2). They in-~I u d e~.~ bioactive glasses such as Bioglass? bioactive glass-ceramics such as Ceravitalo, A/W glass-ceramic, or machineable glass-ceramics; dense HA such as durapatite or Calcitite@*, or bioactive composites such as Palavitat@ §, stainless-steel-fiber-reinforced BioglassB; and PE-HA mixtures. All of these bioactive materials form an interfacial bond with adjacent tissue. However, the time dependence of bonding, the strength of the bond, the mechanism of bonding, and the thickness of the bonding zone differ for the various materials.
It is important to recognize that relatively small changes in the composition of a biomaterial can affect dramatically whether it is bioinert, resorbable, or bioactive. These compositional effects on surface reactions are discussed in Section V.
Nearly Inert Crystalline Bioceramics
High -de nsi t y, hi gh-pu r i t y ( > 9 9.5%) alumina (a-Al2O3) was the first bioceramic widely used clinically. It is used in load-bearing hip prostheses and dental implants because of its combination of excellent corrosion resistance, good biocompatibility, high wear resistance, and high ~t r e n g t h . ' .~~'~-'~ Although some dental implants are single-crystal ~apphire,'~ most alumina devices are very-fine-grained polycrystalline a-Al,O,. A very small amount of magnesia (<0.5%) is used as an aid to sintering and to limit grain growth during sintering. Strength, fatigue resistance, and fracture toughness of polycrystalline a-Al2O3 are a function of grain size and percentage of sintering aid, i.e., purity. Alumina with an average grain size of < 4 prn and >99.7% purity exhibits good flexural strength and excellent compressive strength. These and other physical properties are summarized in Table Ill6 with the International Standards Organization (ISO) requirements for alumina implants. Extensive testing has shown that alumina implants which meet or exceed IS0 standards have excellent resistance to dynamic and impact fatigue and also resist subcritical crack growth.20 An increase in the average grain size to >7 p m can decrease mechanical properties by about 20%. High concentration of sintering aids must be avoided because they remain in the grain boundaries and degrade fatigue resistance, especially in a corrosive physiological environment. ' Methods exist for lifetime predictions and statistical design of proof tests for load-bearing ceramics. Applications of these techniques show that specific prosthesis load limits can be set for an alumina device based upon the flexural strength of the material and its use environment.*' Load-bearing lifetimes of 30 years at 12000-N loads, similar to those expected in hip joints, have been predicted.6 Results from aging and fatigue studies show that it is essential that alumina implants be produced at the highest possible standards of qual- Alumina on alumina load-bearing wearing surfaces, such as in hip prostheses, must have a very high degree of sphericity produced by grinding and polishing the two mating surfaces together. The alumina ball and socket in a hip prosthesis are polished together and used as a pair. The long-term coefficient of friction of an alumina-alumina joint decreases with time and approaches the values of a normal joint. This leads to wear of alumina on alumina articulating surfaces that are nearly 10 times lower than metal-PE surfaces (Fig, 4) .
Low wear rates have led to widespread use in Europe of alumina noncemented cups press fitted into the acetabulum (socket) of the hip. The cups are stabilized by bone growth into grooves or around pegs. The mating femoral ball surface is also of alumina which is bonded to a metallic stem. Long-term results in general are excellent, especially for younger patients. However, Christel et a/.6 caution that stress shielding of the bone can occur. This is due to the high Young's modulus of alumina (Table Ill) , which prevents the bone from being loaded, a requirement for bone to remain healthy and strong. The Young's modulus of cortical bone ranges between 7 and 25 GPa (as discussed in Section X) which is 10 to 50 times lower than aluBioceramics: From Concept to Clinic mina. Christel et a/.6 report that stress shielding may be responsible for cancellous bone atrophy and loosening of the acetabular cup in older patients with senile osteoporosis or rheumatoid arthritis. Consequently, it is essential that the age of the patient, nature of the disease of the joint, and biomechanics of the repair be considered carefully before any prosthesis is used, including those made from alumina ceramics. In the United States, the primary use of alumina is for the ball of the hip joint (Fig. 5) , with the acetabular component being ultrahigh-molecular-weight PE.
Other clinical applications of alumina prostheses, reviewed by Hulbert et a/.,3
include knee prostheses, bone screws, alveolar ridge (jaw bone) and maxillofacial reconstruction, ossicular (middle ear) bone substitutes, keratoprostheses (corneal replacements), segmental bone replacements, and blade and screw and post-type dental implants.
IV. Porous Ceramics
The potential advantage offered by a porous ceramic implant (type 2, Table II, Figs. 1 and 2) is its inertness combined with the mechanical stability of the highly convoluted interface developed when bone grows into the pores of the ceramic. Mechanical requirements of prostheses, however, severely restrict the use of low-strength porous ceramics to low-load-or non-loadbearing applications. Studies show that, when load bearing is not a primary requirement, nearly inert porous ceramics can provide a functional implant,1.3.22-24 When pore sizes exceed 100 pm, bone will grow within the interconnecting pore channels near the surface and maintain its vascularity and long-term viability (Fig. 3) . In this manner the implant serves as a structural bridge and model or scaffold for bone formation. The microstructures of certain corals make an almost ideal investment material for the casting of '' Another interesting coral genus, Goniopora, has a larger pore size, ranging from 200 to 1000 p m The machined coral shape is fired to drive off carbon dioxide from the limestone (CaCO,) forming calcia, while maintaining the microstructure of the original coral The calcia structure serves as an investment material for forming the porous material After the desired material is cast into the pores, the calcia is easily removed from the material by dissolving it in dilute hydrochloric acid The primary advantages of the replamineform process are that the pore size and microstructure are uniform and controlled, and there is complete interconnection of the pores Replamineform porous materials of a-A1203, titania, calcium phosphates, polyurethane silicone rubber, PMMA, and Co-Cr alloys have been used as bone implants with the calcium phosphates being the most acceptable 22 25 Porous ceramic surfaces can also be prepared by mixing soluble metal or salt particles into the surface The pore size and structure are determined by the size and shape of the soluble particles that are subsequently removed with a suitable etchant The porous surface layer produced by this technique is an integral part of the underlying dense ceramic phase Materials such as alumina may also be made porous by using a suitable foaming agent that evolves gases during heating Porous alumina and calcium aluminates used by Hulbert and ~~l l e a g u e s~~~~~ in some of their bone ingrowth studies were produced by mixing powdered calcium carbonate with fine alumina powder A firing time of 20 h at approximately 1450" to 1500°C produced a foamed material with pore size and volume fraction (33% to 48% of porosity) determined by the size and concentration of the original calcium carbonate particles Porous materials are weaker than the equivalent bulk form As the porosity increases the strength of the material decreases rapidly as indicated by the Ryskewitch equation
where ~r is strength v0 IS strength at zero porosity, c is constant, and p is porosity Much surface area is also exposed, so that the effects of the environment on decreasing the strength become much more important than for dense, nonporous materials The in vitro aging of porous alumina in saline solution for periods of 4 weeks as well as in VIVO testing for up to 3 months reduces strength of porous alumina samples by 35% to 40% Permeation into the micropores of seemingly dense alumina can also result in marked reductions in tensile strength Another porous, highstrength ceramic calcia-stabilized zirconia, also undergoes significant decreases in strength with time as do calcium aluminates ' Aging of porous ceramics with their subsequent decrease in strength poses questions as to the successful long-term application of porous materials unless they are designed to be resorbable, e g , are made of calcium salts such as TCP
V. Bioactive Glasses and
Glass-Ceramics Certain compositions of glasses, ceramics, glass-ceramics, and composites have been shown to bond to ese materials have become known as bioactive ce-,4.5.25.41 Some even more specialized compositions of bioactive glasses will bond to soft tissues as well as bone.354' A common characteristic of bioactive glasses and bioactive ceramics is a time-dependent, kinetic modification of the surface that occurs upon implantati~n.~.~ The surface forms a biologically active hydroxycarbonate apatite (HCA) layer which provides the bonding interface with tissues. The HCA phase that forms on bioactive implants is equivalent chemically and structurally to the mineral phase in bone. It is that equivalence which is responsible for interfacial bonding.
Materials that are bioactive develop an adherent interface with tissues that resists substantial mechanical forces. In many cases the interfacial strength of adhesion is equvalent to or greater than the cohesive strength of the implant material or the tissue bonded to the bioactive implant. Figures 6 and 7 show bioactive implants bonded to bone with adherence at the interface sufficient to resist mechanical fracture. Failure occurs either in the implant (Fig. 6 ) or in the bone (Fig. 7 ) but almost never at the interface.
Bonding to bone was first demonstrated for a certain compositional range of bioactive glasses which contained SO,, Na20, CaO, and P20, in specific proportions (Table IV) .I6 There were three key compositional features to these glasses that distinguished them from traditional NanO-CaO-SiOn glasses: (1) less than 60 mol% SO2, (2) high-NanO and high-CaO content, and (3) high-CaO/P,O, ratio. These compositional features made the surbone, July 1991 face highly reactive when exposed to an aqueous medium.
Many bioactive silica glasses are based upon the formula called 45S5
(signifying 45 wt% SO,, S as the network former, and a 5 to 1 molar ratio of Ca to P). Glasses with substantially lower molar ratios of Ca to P (in the form of CaO and P205) do not bond to bone.43 However, substitutions in the 45% formula of 5 to 15 wt% BZO3 for SiO, or 12.5 wt% CaF, for CaO or crystallizing the various bioactive glass compositions to form glass-ceramics has no measurable effect on the ability of the material to form a bone bond.43
However, addition of as little as 3 wt% A1203 to the 45S5 formula prevents bonding. 53' 43-46 The compositional dependence (in weight percent) of bone bonding and soft-tissue bonding for the Na,OCaO-P,O,-SiO, glasses is illustrated in Fig. 8 . All glasses in Fig. 8 The collagenous constituent of soft tissues can strongly adhere to the bioactive silica glasses which lie within the compositional range (dashed line) shown in Fig. 8 . Figure 9 shows collagen from a 10-d in vitro test-tube experiment bonded to a 45% Bioglasso surface by agglomerates of HCA crystallites growing on the surface. The collagen fibrils are woven into the interface by growth of the HCA layer ( Fig. 9(a) ). The dense HCA-collagen agglomerates ( Fig Gross and co-workers5 31 4y 52 have shown that a range of low-alkali (0 to 5 wt%), bioactive silica glass-ceramics (CeravitaP) also bond to bone They find that small additions of Al2O3, Ta205, Ti02, Sb2O3, or Zr02 inhibit bone bonding (Table IV, Fig 1) A two-phase silica-phosphate glass-ceramic com- Table IV for details) Region E (soft-tissue bonding) is inside the dashed line where /+8 ((*) 45% Bioglasse (D) CeravitaP (0) 55843 Bio glass@, and (---) soft-tissue bonding, /B=100/to5bb) posed of apatite (Ca,,(PO4),(OH,F2)) and wollastonite (CaO . Si02) crystals and a residual Si02 glassy matrix, termed AIW glass-ceramic by the Kyoto University team in Japan,34.36-40 also bonds with bone and has very high interfacial bond ~trength.~"' Addition of A1203 or Ti02 to the A/W glassceramic also inhibits bone bonding, whereas incorporation of a second phosphate phase, P-whitlockite (3Ca0. P205), does not.
Another rnultiphase bioactive silicaphosphate glass-ceramic containing phlogopite ((Na,K)Mg3(AISi3Ol0)F2), a mica, and apatite crystals, bonds to bone even though A1203 is present in the c o m p~s i t i o n .~~ However, the A13+ ions are incorporated within the crystal phase and do not alter the surface reaction kinetics of the material. An advantage of these mica-containing glass-ceramics, developed by the Freidrich Schiller University, Jena, Federal Republic of Germany, is their easy ma~hinability.~~ Additional compositions of bioactive glasses have been developed at Abo Akademi, Turku, Finland, for coating onto dental alloy^.^^,^^ 55
Compositions of these various bioactive glasses and glass-ceramics are compared in Table IV .
VI. Interfacial Reaction Kinetics
The literature base for stage 1 (ion exchange) and stage 2 (silica network dissolution) reactions (see Table k July 1991 reaction solutions are also well docuThe effects of glasscrystal interfaces on overall reaction rates have been measured for simple systems,5g but not on complex, multiphase bioactive glass-ceramics or bioactive composites. The original bioactive glass 4595 has been used as a baseline for most surface studies, largely because it is single phase and has only four components (Na,O, CaO, PZO5, Si02). This simple composition (Table IV) also has the highest in vivo bioactivity index (I,) as discussed later. Recent investigat ions 66.70,71 show quite clearly the reaction sequence depicted by Eq. (1) for 45S5 Bioglassm exposed to tris(hydroxymethy1)aminomethane buffer solution (TBS) that does not contain Ca or P ions (TBS). Figures 10 and 11 summarize these findings, determined using Fourier transform infrared (FTIR) spectroscopy of the reacted surface as a function of exposure time. All five reaction stages are clearly delineated by changes in the vibrational modes of merited, 60.61.63.64 Bioceramics: From Concept to Clinic the chemical species in the surface. Figure 10 shows the 45S5 glass surface before reaction (0 h), after 1 h. and after 2 h. The peak identifications are based upon previous assignments of IR spectra.73 75 The alkali-ion-hydrogen-ion exchange and network dissolution (stages 1 and 2 in Table V) very rapidly reduces the intensity of the Si-0-Na and Si-0-Ca vibrational modes and replaces them with Si-OH bonds with one nonbridging oxygen (NBO) ion. Alkali content is depleted to a depth >0.5 p m within a few minutes.
As the stage 1 and 2 reactions continue, the Si-OH single, NBO modes are replaced with (Fig. 11) are largely replaced by a new mode assigned to the Si-0-Si bond vibration between two adjacent SiO, tetrahedra. Thus, this new vibrational mode corresponds to the formation of the silica-gel layer by the stage 3 (Table V) polycondensation reaction between neighboring surface silanol groups. This mode decreases in frequency until it is hidden by the growing apatite layer after 1 h.
As early as 10 min, a P-0 bending vibration associated with formation of an amorphous calcium phosphate layer appears. This is due to precipitation from solution (stage 4 in Table V) . Table V ing vibration is strong and exhibits a continually decreasing frequency as the calcium phosphate-rich layer builds. At about 1.5&0.2 h, the P-0 bending vibration associated with the amorphous calcium phosphate layer is replaced with two P -0 modes assigned to crystalline apatite. Concurrent with the onset of apatite crystallization (stage 5 in Table V) July 1991 phosphate-rich layer was present for Ceravi t al@-t ype glass-ceram ic s .
Hohland et reported a calcium phosphate-rich layer at the bone interface with a glass-ceramic composed of phologopite and apatite crystals. Kokubo and c o -~o r k e r s~~~~ also demonstrated that CaO-SiOz-based glasses, without phosphate, formed an apatite layer on their surface when exposed for 2 to 30 d in simulated body fluid that contained only 1.OmM HPOi-. The CaO-Si02 glasses were confirmed to bond to living bone by the surface apatite layer.77 Previously Ogino, Ohuchi, and the showed that P,O,-free Na,O-SiO, glasses formed an apatite layer on their surface when exposed to an aqueous solution containing calcium and phosphate ions. Recently, Li, Clark, and the author7' demonstrated that glasses containing primarily SiO,, with only 10 mol% of CaO and Pz05 and no Na20 formed apatite layers in a tris buffer solution. Earlier, Walker" demonstrated that even nearly pure SiOz eventually formed a bone bond if the surface had a very high surface area, >400 m2/g. Unfortunately, the interface was not analyzed for the presence of an interfacial apatite layer which could have been nucleated on the surface by hydroxylation andlor dissolution of soluble 30,. For years it has been known that synthetic HA implants, which contain no SiO, or alkali ions, will bond to bone by forming a new epitaxial apatite phase at the interface,'0~8',82 as discussed in a later sect ion.
Consequently, we conclude that bioactivity occurs only within certain compositional limits and very specific ratios of oxides in the Na20-KzOCa0-Mg0-P,O,-SiO2 systems; however, the extent of these compositional limits and the physical, chemical, and biochemical reasons for the limits are poorly known at present.
We do know that, for a bond with tissues to occur, a layer of biologically active HCA must form. This is perhaps the only common characteristic of all the known bioactive implant materials. It is the rate of HCA formation (stage 4) and the time for onset of crystallization (stage 5) that varies so greatly. When the rate becomes excessively slow, no bond forms and the material is no longer bioactive. Compositional effects on stages 4 and 5 appear to be critical in controlling bonding, nonbonding, or resorption. Our next step in understanding is to relate the implant surface reactions to in vivo response.
VIII. Relation of Surface Kinetics
to Rate of Bone Bonding By changing the compositionally controlled reaction kinetics (Table V) , the rates of formation of hard tissue at a bioactive implant interface can be al- The compositional dependence of lB (Fig 1) shows that there are isole contours within the bioactivity boundary, as shown in Fig 8 4 The change of IB with Si02/(Na,0+CaO) ratio is very large as the bioactivity boundary is approached, at 60%-StO2lB -0 Addltion of multivalent ions to a bioactive glass or glass-ceramic will serve to shrink the isoIB contours Thus, the isole contours decrease as the percentage of A1203 TanO,, and ZrO, increases in the material Consequently, the isolB 
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Boneand soft-tissue bonding depending on the progenitor stem cells in contact with the implant. This soft-tissue critical isol, limit is shown by the dashed contour in Fig. 8 , based on the work of Wilson and N~lletti.~ ' The thickness of the bonding zone between a bioactive implant and bone is proportional to its I s value (compare Fig. 1 with Fig. 2) . Figure 13 shows an optical micrograph of the interface of 45S5 Bioglasss bonded to bone (rat tibia) after 1 year and an electron microprobe analysis of the interface. The bulk bioactive glass implant (BG), silica-rich layer (S), HCA layer (CA, P), and bone (B) are indicated. Living bone cells (osteocytes labeled 0) are at the interface. There is no seam of interfacial fibrous tissue. Even at the electron microscopic level there is almost no unmineralized tissue at the bonding interface, as reviewed by Gross et aL5 and Hench and Clark.44 The thickness of the bonding region is about 100 pm.
In summary, the reaction stages that appear to be involved in forming the bond of bioactive glasses and bioactive glass-ceramics with tissues are depicted in Fig. 14 The failure strength of a bioactively fixed bond appears to be a nonlinear function of the I B value of the implant. Instead, interfacial strength appears to be inversely dependent on the thickness of the bonding zone. For example, 45% Bioglasse with a very high lB value develops a gel-bonding layer of 100 p m (Fig. 13) which has a relatively low shear strength. In contrast, A/W glass-ceramic, with an intermediate lB value has a bonding interface in the range of 10 to 20 p m and a very high resistance to shear (see Fig. 7) . Thus, the interfacial bonding strength appears to be optimum for I B values of -4. However, it is important to recognize that the interfacial area for bonding is time dependent, as shown in Fig. 1 Table VI ). The 8-year history of successful use of CeravitaP glassceramics and 4595 Bioglass@ implants in middle-ear surgery to replace ossicles damaged by chronic infection, reported by R e~k , '~ Merwin,86 and D o~e k , '~ are especially encouraging as is the use of A/W glass-ceramic in replacing the iliac crest and in vertebral surgery by Y a m a m~r o .~~~~~~'~ 45S5 Bioglass@ implants have been used sucessfully for maintenance of the alveolar ridge for denture wearers for up to 7 yearsg0 with nearly a 90% retention rate, as reported by Stanley et a/." Many patients are profoundly deaf because of loss of the auditory nerve fibers in the cochlea. Research has shown that such patients can still "hear" electronic impulses applied to the cochlea, although at much lower frequency discrimination. These findings have led to the development of an extracochlear electrical implant which delivers electrical signals in real time encoded by a computer to match speech pattern^.^' A team led by Fourcin and Douek in London reportg' successful clinical use of an array of four platinum electrodes, insulated by medical-grade alumina and anchored in the bone with a 45S5 Bioglass@ sleeve. The alumina provides mechanical and dielectric stability to the device and the bioactive glass bonds both to the bone and the soft connective tissues as it protrudes through the skin. This hermetic, percutaneous living seal both provides mechanical stability and preBiocerumics: From Concept fo Clinic vents infection from migrating down the electrodes thereby protecting the patient, who must untiug the electronics at night. Figure 15(a) shows the University of London extracochlear electrode array and its implantation site. Figure 15(b) shows the implant in place in a patient.
IX. Calcium Phosphate Ceramics
Calcium phosphate-based bioceramics have been in use in medicine and dentistry for nearly 20 years, as reviewed by Hulbert et a/.,3 de G r~o t , '~"~ de Groot and Le Geros," J a r~h o ,~~ and Williams.8z Applications include dental implants, percutaneous devices, and use in periodontal treatment, alveolar ridge augmentation, orthopedics, maxillofacial surgery, otolaryngology, and spinal surgery (Table VI) . Different phases of calcium phosphate ceramics are used depending upon whether a resorbable or bioactive material is desired.
The stable phases of calcium phosphate ceramics depend considerably upon temperature and the presence of water, either during processing or in the use environment. At body temperature only two calcium phosphates are stable in contact with aqueous media, such as body fluids; at pH <4.2 the stable phase is CaHPO, . 2H20 (dicalcium phosphaten or brushite, C2P), whereas at pH 24.2 the stable phase is Ca,0(P04)6(OH)2 (HA). At higher temperatures other phases, such as Ca,( P04)2 (p-tricalcium phosphate, C3P, or TCP) and Ca4Pz0, (tetracalcium phosphate, C,P) are present. The unhydrated high-temperature calcium phosphate phases interact with water, or body fluids, at 37°C to form HA. The HA forms on exposed surfaces of TCP by the following reaction:
Thus, the solubility of a TCP surface approaches the solubility of HA and decreases the pH of the solution which further increases the solubility of TCP and enhances resorption. Williamse2 discusses the importance of the Ca/P ratio in determining solubility and tendency for resorbtion in the body. The presence of micropores in the sintered material can increase the solubility of these phases." 13, 33 Sintering of calcium phosphate ceramics usually occurs in the range of 1000" to 1500°C following compaction of the powder into a desired shape.33 The phases formed at high temperature depend not only on temperature but also on the partial pressure of water in the sintering atmosphere. With water present, HA can be formed and is a stable phase up to 136OoC, as shown in the phase equilibrium diagram for CaO and P 2 0 5 with 500-mmHg (-66-kPa) partial pressure of water (Fig 16) Without water, C4P and C3P are the stable phases The temperature range of stability of HA increases with the partial pressure of water as does the rate of phase transitions of C3P or C4P to HA Because of kinetics barriers which affect the rates of formation of the stable calcium phosphate phases it IS often difficult to predict the volume fraction of hightemperature phases that are formed during sintering and their relative stability when cooled to room temperature Starting powders can be made by mixing into an aqeous solution the appropriate molar ratios of calcium nitrate and ammonium phosphate which yield a precipitate of stoichiometric HA. The Ca", PO:-, and OH-ions can be replaced by other ions during processing or in physiological surroundings; e . g . , fluorapatite, Ca,,(P04)s(OH)2~, where O<x<2 and carbonate apatite, Ca,0(P04)6(OH)2-2x-(C03), or Ca,o-x+V(P04)s-,(0H)~-,-2y where O<x<2 and O<y<O.5x can be formed. Fluorapatite is found in dental enamel and HCA is present in bone. For a discussion of the structure of these complex crystals see Ref. 81 (Le Geros) .
The mechanical behavior of calcium phosphate ceramics strongly influences their application as implants." Tensile and compressive strength and fatigue resistance depend on the total volume of porosity. Porosity can be in the form of micropores (<1 p m in diameter, due to incomplete sintering) or macropores (>I00 ,urn in diameter, created to permit bone growth). The dependence of Compressive strength 
where V, is in the range 0 to 0.5. Tensile strength (u,) depends greatly on the volume fraction of microporosity (Vm).
The Weibull factor (n) of HA implants is low in physiological solutions (n=12), which indicates low reliability under tensile loads. Consequently, in clinical practice calcium phosphate bioceramics should be used as (1) powders, (2) small, unloaded implants such as in the middle ear, (3) dental implants with reinforcing metal posts, (4) coatings on metal implants, (5) low-loaded porous implants where bone growth acts as a reinforcing phase, or (6) the bioactive phase in a polymer-bioactive ceramic composite.
The bonding mechanisms of dense HA implants appear to be very different from those described earlier for bioactive glasses. Evidence for the bonding process for HA implants is reviewed by J a r~h o .~~ A cellular bone matrix from differentiated osteoblasts appears at the surface, producing a narrow amorphous electron-dense band only 3 to 5 p m wide. Between this area and the cells, collagen bundles are seen. Bone mineral crystals have been identified in this otherwise amorphous area.g' As the site matures, the bonding zone shrinks to a depth of only 0.05 to 0.2 pm. The result is normal bone attached through a thin epitaxial bonding layer to the bulk implant." Ogiso et a / . 9 3 9 4 have shown, through transmission electron microscopy (TEM) lattice image analysis of dense HA bone interfaces, an almost perfect epitaxial alignment of the growing bone crystallites with the apatite crystals in the implant (Fig. 17) .
A consequence of this ultrathin bonding zone is a very high gradient in elastic modulus at the bonding interface between HA and bone. This is one of the major differences between the bioactive apatites and the bioactive glasses and glass-ceramics, as illustrated in Fig. 2 . The implications of this difference on the interfacial response of the implant to applied stress and bone vitality is discussed in Ref. 1 (Ch. 14). The significance of this difference clinically is as yet unknown.
Potentially, one of the most important applications of sintered, dense HA implants is as percutaneous access assist devices (PAD)95 for continuous ambulatory peritoneal dialysis (CAPD) patients. There are hundreds of thousands of patients worldwide who undergo renal dialysis and could benefit from CAPD, which would decrease their dependency on the resources required for conventional hemodialysi~.~~ However, a severe limitation on CAPD is the incidence of peritonitis, up to 1.5 incidents per year per patient, usually caused by invasion of bacteria along the wall of the inserted peritoneal catheter. Catheters used, now made of silicone rubber, do not form a completely sealed junction with the skin or subcutaneous tissues and thereby provide a pathway for infection to occur.
Aoki and c011eagues~~~~~ have shown that a dense, sintered HA implant, used in contact with skin and subcutaneous tissues, provides a stable seal and has prevented downgrowth of epidermis and infiltration of cells, common characteristics of glassy carbon or silicone rubber percutaneous leads. Figure 18 shows a HA implant in the arm of a volunteer after 6 years without any serious infection. X-ray computer tomography of the forearm showed no calcification of the soft tissues around the skin button.97 Two patients suffering from endstage renal disease developed arteriovenous fistulas after 10 months and 12 years hemodialysis, and therefore, could not continue treatment. After implantation of an HA PAD and CAPD treatment, they have remained well for more than 2 years,96 indicating the value of this application of bioactive ceramics.
X. Composites
One of the primary restrictions on clinical use of bioceramics is the uncertain lifetime under the complex stress
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Vol. 14, No. I cases the goal is to increase flexural strength and strain to failure and decrease elastic modulus. Bonfield'"' argues that analogous implant materials with similar mechanical properties should be the goal when bone is to be replaced Because of the anisotropic deformation and fracture characteristics of cortical bone, which is itself a composite of compliant collagen fibrils and brittle HCA crystals, the Young's modulus ( E ) varies between -7 to 25 GPa, the critical stress intensity ranges from -2 to 12 MPa'm' '' , and the critical strain intensity increases from as low as -600 J . m -2 to as much as 5000 J.m-2, depending on orientation, age, and test c~n d i t i o n . '~~ In contrast, most bioceramics are much stiffer than bone and many exhibit poor fracture toughness (Table Ill) . Consequently, one approach to achieve properites analogous to bone is to stiffen a compliant biocompatible synthetic polymer, such as PE, with a higher modulus ceramic second phase, such as HA powder."' The effect is to increase Young's modulus from 1 to 8 GPa and to decrease the strain to failure from >90% to 3% (Fig. 19) as the volume fraction of HA increases to 0.5. The transition from ductile to brittle behavior occurs between 0.4 and 0.45 volume fraction HA. Bonfield"" reported that the ultimate tensile strength of the composite remained within the range of 22 to 26 MPa. At 0.45 volume fraction HA, the Klc value was 2.920.3 MPa m1'2, whereas at <0.4 volume fraction HA the fracture toughness was considerably greater, because of the ductile deformation associated with crack propagation. Thus, the mechanical properties of the PE-HA composite are close to or superior to those of bone.
The bioactive phase is exposed by machining the surface of the composite. Implant tests of the PE+0.4HA composites have demonstrated development of bone bonding between the natural hard tissue and the synthetic implant.'04 An application of the PE-HA composite currently in test in London is as a medullary sleeve for fixation of the stem of femoral head replacements, where the bonding of the composite to bone should prevent stress shielding because of its match of Young's moduIus with the bone. Figure 20 depicts such a device.
Another promising approach toward achieving high toughness, ductility, and a Young's modulus matching that of bone was developed by Ducheyne and the author.lo7 This composite uses sintered 316L stainless steel of 50-, 100-, or 2 0 0 -~m diameter or titanium fibers, which provide an interconnected fibrous matrix which is then impregnated with molten 4585 Bioglass@'. After the composite is cooled and annealed, a very strong and tough material results, with Table Vlll , indicate the great potential of bioactive and resorbable bioceramics with good mechanical behavior for a wide variety of clinical applications. As yet, however, very little data exist on the environmental sensitivity and fatigue life of these composite systems under physiological loads and environments. Until these data are acquired caution must be excercised when using such materials climcal\y, other than in high\y controlled trials.
XI. Coatings (1) Carbon
Bokrosiog applied, in 1967, for a patent describing the medical use of pyrolytic carbon coatings on metal substrates. The coatings were used in heart surgery soon thereafter."' The first time the low-temperature isotropic (LTI) carbon coatings were used in humans was as a prosthetic heart valve by DeBakey in 1969." ' Almost all commonly used prosthetic heart valves today have LTI carbon coatings for the orifice and/or occluder (Fig. 22) because of their excellent resistance to blood clot formation and long fatigue life."' More than 600 000 lives have been prolonged through the use of this bioceramic in heart valves.
Three types of carbon are used in biomedical devices: the LTI variety of pyrolytic carbon, glassy (vitreous) carbon, and the ultralow-temperature isotropic (ULTI) form of vapordeposited ~arbon."'~"~ These carbon materials are integral and monolithic materials (glassy carbon and LTI carbon) or impermeable thin coatings (ULTI carbon). These three forms do not suffer from the integrity problems typical of other available carbon materials. With the exception of the LTI carbons codeposited with silicon, all the carbon materials in clinical use are pure elemental carbon. Up to 20 wt% silicon has been added to LTI carbon without significantly affecting the biocompatibility of the material. The composition, structure, and fabrication of the three clinically relevant carbons are unique when compared with the more common, naturally occurring form of carbon (i.e., graphite) and other industrial forms produced from pure elemental carbon.
The LTI, ULTI, and glassy carbons are subcrystalline forms and represent :oated heart valves. (Photograph a lower degree of crystal perfection. There is no order between the layers such as there is in graphite; therefore, the crystal structure of these carbons is two dimensional. Such a structure, called turbostratic, has densities between about 1400 and 2100 kg.m-3. High-density LTI carbons are the strongest bulk forms of carbon and their strength can further be increased by adding silicon. ULTl carbon can also be produced with high densities and strengths, but it is available only as a thin coating (0.1 to 1.0 pm) of pure carbon. Glassy carbon is inherently a low-density material and, as such, is weak. Its strength cannot be increased through processing. Processing of all three types of medical carbons are discussed in Ref. 113 (Haubold et a/. ).
The mechanical properties of the various carbons are intimately related to their microstructures. In an isotropic carbon, it is possible to generate materials with low elastic moduli (20 GPa) and high flexural strength (275 to 620 MPa). There are many benefits as a result of this combination of properties; e.g., large strains (-2%) are possible without fracture. The turbostratic carbons are very tough when compared with ceramics such as aluminum oxide. The energy to fracture for LTI carbon is approximately 5.5 MJ.m-3, compared with 0.18 MJ.m-3 for aluminum oxide; i.e., the carbon is approximately 25 times as tough. The strain to fracture for the vapor-deposited carbons is greater than 5.0%, making it feasible to coat highly flexible polymeric materials such as PE, polyesters, and nylon without fear of fracturing the coating when the substrate is flexed.
The turbostractic carbon materials have extremely good wear resistance, some of which can be attributed to their toughness, i,e., their capacity to sustain large local elastic strains under concentrated or point loading without galling or incurring surface damage. The bond strength of the ULTl carbon to stainless steel and to Ti-6AI-4V exceeds 70 MPa as measured with a thin-film adhesion tester. This excellent bond is, in part, achieved through the formation of interfacial carbides. The ULTl carbon coating generally has a lower bond strength with materials that do not form carbides.
Another unique characteristic of the turbostratic carbons is that they do not fail in fatigue. The ultimate strength of turbostratic carbon, as opposed to metals, does not degrade with cyclical loading. The fatigue strength of these carbon structures is equal to the singlecycle fracture strength. It appears that, unlike other crystalline solids, these forms of carbon do not contain mobile defects, which at normal temperatures can move and provide a mechansim for the initiation of a fatigue crack.
The more important known properties of the turbostratic carbons are listed in Ref. 113 .
Carbon surfaces are not only thromboresistant, but also appear to be compatible with the cellular elements of blood; they do not influence plasma proteins or alter the activity of plasma enzymes. One of the proposed explanations for the blood compatibility of these materials is that they adsorb blood proteins on their surface without altering them.
Reference 113 summarizes the uses of glassy, LTI, and ULTl carbons in various medical areas.
(2) Hydroxyapatite
A second bioceramic coating which has reached a significant level of clinical application is the use of HA as a coating on porous metal surfaces for fixation of orthopedic prostheses. This approach combines types 2 and 3 methods of fixation (Table II) and originates from the observations of Ducheyne and colleague^,^ in 1980, that HA powder in the pores of a porous, coated-metal implant would significantly affect the rate and vitality of bone ingrowth into the pores. A large number of investigators have explored various means of applying the HA coating, as discussed in Refs. 3, 5, 12, 25, 41 , and 101, with plasma spray coating generally being preferred. There is a substantial enhancement of the early stage interfacial bond strength of implants with a plasma-sprayed HA coating when compared with porous metals without the coating, as illustrated in Fig. 23 The rate of biodegradation increases as (1) surface area increases (powders>porous solid>dense solid), (2) crystallinity decreases, (3) crystal perfection decreases, (4) crystal and grain size decrease, and (5) ionic substitutions of CO,'-, Mg", Srz+ in HA take place. Factors which result in a decreasing rate of biodegradation include (1) F-substitution in HA, (2) Mg2+ substitution in 0-TCP, and (3) decreasing p-TCP/HA ratios in biphasic calcium phosphates. Because of these variables it is necessary to control the microstructure and phase state of a resorbable calcium phosphate bioceramic in addition to achieving precise compositional control to produce a given rate of resorption in the body. As yet, there are few data on the kinetics of these reactions and the variables influencing the kinetics.
XIII. Therapeutic Applications
A significant problem in the radiation treatment of cancer is the serious systemic side effects. Localization of the radiation at the site of the tumor decreases the radiation dosage required to kill the cancer cells and thereby minimizes side-effect toxicities. An innovative approach to the localized delivery of radioactive yttrium-90 ("Y) to treat liver cancer has been developed by Day1l4 at the University of MissouriRolla using glass microspheres. A yttria-aluminosilicate glass, containing *'Y is made in the form of 25-pm microspheres. Prior to use in hepatic arterial infusion therapy, the microspheres are bombarded by neutrons which creates ' OY, a radioactive isotope which is a short half-life (64 h), short- Dayi16 reports that the glassmicrosphere radiation delivery vehicle can be modified with different radioactive isotopes to achieve various ranges and is being tested preclinically for treatment of kidney cancer and arthritis.
Another approach to cancer treatment using bioceramics is under development by Yamamuro in Kyoto, Japan." ' Ohura et have incorporated 40 wt% Fe20, in a bioactive glass-ceramic composed of CaOSi02-B,0,-P205. The magnetite phase produces a high-saturation magnetization which can be used to generate localized heating at an implant site. Temperatures of >42"C can be generated in bone, sufficient to kill tumor cells, by applying a 300-0e, 100-Hz magnetic field. The wollastonite phase which grows during crystallization provides bonding of the granules to bone. Preclinical tests are underway.
Still another therapeutic application of bioceramics is delivery of various steroid hormones from aluminum calcium phosphate porous The advantage of this method is sustained delivery of a potentially toxic substance over long periods of time, again inhibiting systemic side effects
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XIV. Summary
Bioceramics has evolved to become an integral and vital segment of our modern health-care delivery system. The full potential is only beginning to be recognized. In the years to come the composition, microstructure, and molecular surface chemistry of various types of bioceramics will be tailored to match the specific biological and metabolic requirements of tissues or disease states. This "molecular-based pharmaceutical" approach to the design of bioceramics should couple with the growth of genetic engineering, sensor technology, and information processing, resulting in a range of products and applications not even imagined at present, but potentially beneficial to millions of people annually.
However Tables IV,  VIII , or IX. Likewise, there is no basis to compare fatigue life for any of these materials or establishing the relative importance of grain-boundary attack or slow crack growth under standardized conditions We must correct these deficiencies within this decade because there is a rapidly growing number of failures of load-bearing metallic prostheses with poly(methy1 methacrylate) (PMMA) cement fixation. The lifetime of cemented devices is often less than the lifetime of a patient. Therefore, revision surgery is required with great trauma t o the patient and great expense to our health-care system. Bioceramics offer one of the few alternatives for solving this problem. However, it is our responsibility to assure that long-term reliability of bioceramics 
